Table 1.
Clinical patients' characteristics
| Pat.No.FACS Figure 1 | Pat.No.ADCC Figure 2 | Diagnosis | Disease stage | Sex (female/male) | Staging parameter | Before ECP | After ECP | Overall response | Responder (R)/ Non-Responder (N) | ECP stopped/continued |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | SS | stage IVA1 | F | CD4:CD8 | 47.5 | 2.1 | CR | R | stopped due to remission |
| T4N1M0B2 | CD4+ CD26-/CD7- (cells/µl) | 6605 | 158 | |||||||
| CD4+ CD26-/CD7- (%) | 97 | 40 | ||||||||
| Blood stage | B2 | B0 | ||||||||
| 2 | - | SS | stage IVA1 | F | CD4:CD8 | 82 | 93 | SD | N | stopped due to death |
| T4N1bM0B2 | CD4+ CD26-/CD7- (cells/µl) | 582 | 1202 | |||||||
| CD4+ CD26-/CD7- (%) | 51 | 45 | ||||||||
| Blood stage | B1 | B2 | ||||||||
| 3 | 3 | SS | stage IVA1 | F | CD4:CD8 | 47.5 | 47.5 | PR | R | stopped due to patients’ wish |
| T4N0M0B2 | CD4+ CD26-/CD7- (cells/µl) | 9790 | 4736 | |||||||
| CD4+ CD26-/CD7- (%) | 93 | 44 | ||||||||
| Blood stage | B2 | B2 | ||||||||
| 4 | 4 | SS | stage IVA1 | M | CD4:CD8 | 15.2 | 8.4 | PR | R | stopped due to inclusion in |
| T4NxM0B2 | CD4+ CD26-/CD7- (cells/µl) | 4657 | 1243 | clinical trial | ||||||
| CD4+ CD26-/CD7- (%) | 72 | 73 | ||||||||
| Blood stage | B2 | B2 | ||||||||
| 5 | 5 | SS | stage IVA1 | F | CD4:CD8 | 48 | 47.5 | SD | N | stopped due to lost to follow up |
| T4NxM0B | CD4+ CD26-/CD7- (cells/µl) | 11135 | 5939 | |||||||
| CD4+ CD26-/CD7- (%) | 94 | 94 | ||||||||
| Blood stage | B2 | B2 | ||||||||
| 6 | 6 | SS | stage IVA1 | F | CD4:CD8 | 4.6 | 8.2 | SD | N | continued (since 4.5 years) |
| T4NxM0B | CD4+ CD26-/CD7- (cells/µl) | 989 | 1540 | |||||||
| CD4+ CD26-/CD7- (%) | 49 | 81 | ||||||||
| Blood stage | B1 | B2 | ||||||||
| 7 | 7 | SS | stage IVA1 | F | CD4:CD8 | 1.1 | 1.9 | SD | N | stopped due to lost to follow up |
| T4NxM0B2 | CD4+ CD26-/CD7- (cells/µl) | 346 | 381 | |||||||
| CD4+ CD26-/CD7- (%) | 57 | 64 | ||||||||
| Blood stage | B1 | B1 | ||||||||
| 8 | 8 | SS | stage IVA1 | F | CD4:CD8 | 44.2 | 31 | SD | N | stopped due to inclusion in |
| T4NxM0B2 | CD4+ CD26-/CD7- (cells/µl) | 3556 | 5424 | clinical trial | ||||||
| CD4+ CD26-/CD7- (%) | 92 | 96 | ||||||||
| Blood stage | B2 | B2 | ||||||||
| 9 | 9 | SS | stage IVA1 | M | CD4:CD8 | 6.8 | 5 | CR | R | continued (since 1.5 years) |
| T4N0M0B2 | CD4+ CD26-/CD7- (cells/µl) | 1529 | 226 | |||||||
| CD4+ CD26-/CD7- (%) | 78 | 39 | ||||||||
| Blood stage | B2 | B0 | ||||||||
| - | 10 | SS | stage IVA1 | F | CD4:CD8 | 10.4 | 48.5 | SD | N | continued, plus additonal |
| T4N1M0B2 | CD4+ CD26-/CD7- (cells/µl) | 1923 | 3876 | therapy with MTX | ||||||
| CD4+ CD26-/CD7- (%) | 77 | 86 | ||||||||
| Blood stage | B2 | B2 | ||||||||
| - | 11 | SS | stage IVA1 | M | CD4:CD8 | 14.3 | 7.3 | PR | R | continued (since 4 years) |
| T4N1M0B2 | CD4+ CD26-/CD7- (cells/µl) | 2356 | 541 | |||||||
| CD4+ CD26-/CD7- (%) | 91 | 59 | ||||||||
| Blood stage | B2 | B1 | ||||||||
| - | 12 | SS | stage IVA2 | M | CD4:CD8 | 1.5 | 1.2 | SD | N | continued (since 3 years) |
| T4N3M0B2 | CD4+ CD26-/CD7- (cells/µl) | 900 | 1451 | |||||||
| CD4+ CD26-/CD7- (%) | 73 | 64 | ||||||||
| Blood stage | B1 | B2 | ||||||||
| - | 13 | SS | stage IVA1 | M | CD4:CD8 | 1.1 | 2 | SD | N | stopped due to death |
| T4N0M0B2 | CD4+ CD26-/CD7- (cells/µl) | 133 | 90 | |||||||
| CD4+ CD26-/CD7- (%) | 46 | 61 | ||||||||
| Blood stage | B0 | B0 |
MTX: Methotrexate
Responder: CR, PR
Non-responder: SD, PD
SS: Sezary Syndrome
ECP: Extracorporeal photopheresis
CR: complete response
PR: partial response
SD: stable disease
PD: progressive disease